MEDICAL IMAGING REAGENTS MARKET ANALYSIS

Leading Companies

Bayer AG, Bracco SpA, Eli Lilly and Company, General Electric Company (GE Healthcare), among others.

Global Medical Imaging Reagents Market: Key Developments

In April 2022, Becton, Dickinson and Company (BD) announced the launch of the new range of reagents, BD Horizon RealYellow 586 Reagents. The new reagents will allow researchers to gain improved data resolution and greater insights from samples compared to traditional fluorochromes. BD Horizon RealYellow 586 Reagents are capable to boost the drug discovery and development in oncology, autoimmune disorders, and infectious diseases.

In March 2022, Mylab Discovery Solutions announced its plans to launch entire range of routine diagnostic kits and devices in conventional and POCT format. With this expansion in product lines, now the labs can use Mylab’s devices and reagents to do all routine tests such as cardiac profile, kidney function tests, liver, urine, hormone, and fever panels, cancer markers, and much more.

In February 2021, PerkinElmer, Inc. launched the first cell painting kit as part of its new portfolio of PhenoVue cellular imaging reagents. This range of reagents leverages PerkinElmer’s expertise in cellular imaging and high-content screening and works alongside the company’s micro-plates, automation, software and industry-leading high-content screening instruments.

Global Medical Imaging Reagents Market: Key Companies Insights

The global medical imaging reagents market is highly competitive. This is attributed to the rise in demand for medical imaging reagents worldwide, as a result, players in the market are focusing on launching novel products in the market.

Some of the key players in the global medical imaging reagents market are Bayer AG, Bracco SpA, Eli Lilly and Company, General Electric Company (GE Healthcare), among others.